Neural Therapeutics Inc.
NURL
CNSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 120.72% | 100.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 107.75% | 13.99% | |||
| Operating Income | -107.75% | -13.99% | |||
| Income Before Tax | -747.48% | -10.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -747.48% | -10.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -747.48% | -10.58% | |||
| EBIT | -107.75% | -13.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -625.00% | -9.09% | |||
| Normalized Basic EPS | -100.00% | -14.29% | |||
| EPS Diluted | -625.00% | -9.09% | |||
| Normalized Diluted EPS | -100.00% | -14.29% | |||
| Average Basic Shares Outstanding | 19.16% | 1.15% | |||
| Average Diluted Shares Outstanding | 19.16% | 1.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||